Is there a progression‐free survival benefit of first‐line crizotinib versus standard chemotherapy and second‐line crizotinib in ALK‐positive advanced lung adenocarcinoma? A retrospective study of Chinese patients

Samankaltaisia teoksia

• Feasibility of continuing crizotinib therapy after RECIST-PD in advanced non-small cell lung cancer patients with ALK/ROS-1 mutations
  Tekijä: Liu, Jun, et al.
  Julkaistu: (2018)
• Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer
  Tekijä: Cui, Shaohua, et al.
  Julkaistu: (2016)
• Ceritinib in second and further lines of therapy in advanced ALK mutant adenocarcinoma
  Tekijä: Losonczy, György
  Julkaistu: (2016)
• Factors that predict progression-free survival in Chinese lung adenocarcinoma patients treated with epidermal growth factor receptor tyrosine kinase inhibitors
  Tekijä: Cui, Shaohua, et al.
  Julkaistu: (2016)
• Alectinib can replace crizotinib as standard first-line therapy for ALK-positive lung cancer
  Tekijä: Uemura, Takehiro, et al.
  Julkaistu: (2017)